A Pilot Safety and Feasibility Study of Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function.

This document provides information about a clinical trial for the treatment of multiple myeloma, a type of cancer. The trial aims to test the effectiveness of a combination of drugs and radiation therapy as a lymphodepleting regimen prior to CAR T therapy for multiple myeloma patients with impaired renal function. The trial is set to begin on November 30, 2024, and is expected to be completed by March 31, 2026. The eligibility criteria for participants include having a confirmed diagnosis of multiple myeloma and meeting certain health requirements. The trial is being conducted in the United States and is regulated by the U.S. FDA, with Dr. Michael J Slade from Washington University School of Medicine as the principal investigator. [Extracted from the article]